Objectives To study therapeutic efficacy and safety of high dose clopidogrel in patients with coronary heart diseases (CHD) who underwent elective percutaneous coronary intervention (PCI).
Methods A total of 173 CHD patients underwent PCI were divided into strong clopidogrel group (received 600 mg of plavix, n = 87) and standard clopidogrel group (received 300 mg of plavix, n = 86). Before PCI, the two groups were respectively given 600 mg and 300 mg of plavix, They were respectively given 150 and 75 mg every day for 7 days after PCI; Then they were all given 75 mg every day over one year. Therapeutic efficacy and occurrence of adverse reactions were observed in the two groups.
Results There were significant difference in complete revascularisation rate (93.8% vs. 87.2%, P < 0.05), major adverse cardiovascular-cerebral events (MACCE) (2.0% vs. 6.8%, P < 0.001), There were no differences in bleeding and vascular complications (1.6% vs. 1.7%, P > 0.05) between strong clopidogrel group and standard clopidogrel group.
Conclusions Strong clopidogrel is more effective and safe than standard clopidogrel in elective PCI of CHD.